CDK inhibitors for cancer treatment are on the horizon, with some drugs having multi‐specific CDK inhibitor activity such as dinaciclib,21 and others having CDK12‐specific inhibition such as THZ53122 and SR‐4835.23 This evidence concerns the gene CDK12 and cancer.